Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXOTCMKTS:ETSTNASDAQ:GNFTNASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$1.97+6.2%$2.08$1.29▼$7.85$216.14M1.241.81 million shs1.59 million shsETSTEarth Science Tech$0.14-20.0%$0.14$0.00▼$0.33$42.38M1.64120,632 shs26,893 shsGNFTGenfit$4.28+4.9%$3.52$2.55▼$6.42$213.88M0.9214,869 shs3,470 shsSOPHSOPHiA GENETICS$3.03+0.3%$3.10$2.58▼$6.28$202.06M1.0265,160 shs30,884 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+6.20%+4.79%+0.51%-48.70%-58.53%ETSTEarth Science Tech-20.00%-20.00%+10.77%-12.73%+51.58%GNFTGenfit+4.90%+17.58%+25.88%+14.75%+25.88%SOPHSOPHiA GENETICS+0.33%-4.11%-7.90%-13.43%-39.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.0826 of 5 stars3.51.00.00.02.61.70.6ETSTEarth Science TechN/AN/AN/AN/AN/AN/AN/AN/AGNFTGenfit1.2407 of 5 stars3.52.00.00.00.90.00.0SOPHSOPHiA GENETICS2.5287 of 5 stars3.45.00.00.02.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$18.67847.55% UpsideETSTEarth Science Tech 0.00N/AN/AN/AGNFTGenfit 3.00Buy$13.00203.74% UpsideSOPHSOPHiA GENETICS 2.75Moderate Buy$6.80124.42% UpsideCurrent Analyst Ratings BreakdownLatest ETST, GNFT, ANNX, and SOPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2025SOPHSOPHiA GENETICSBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.003/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/7/2025GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AETSTEarth Science Tech$11.95M3.55N/AN/A$0.01 per share14.40GNFTGenfit$67.00M3.19N/AN/A$1.48 per share2.89SOPHSOPHiA GENETICS$65.17M3.10N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%5/12/2025 (Estimated)ETSTEarth Science Tech$810KN/A0.00∞N/AN/AN/AN/AN/AGNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/AN/ASOPHSOPHiA GENETICS-$78.98M-$0.95N/AN/AN/A-110.71%-55.06%-38.33%5/6/2025 (Estimated)Latest ETST, GNFT, ANNX, and SOPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ANNXAnnexon-$0.30N/AN/AN/AN/AN/A5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21N/AN/AN/A$16.76 millionN/A3/4/2025Q4 2024SOPHSOPHiA GENETICS-$0.23-$0.23N/A-$0.23$17.71 million$17.73 million3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18ETSTEarth Science Tech0.010.871.09GNFTGenfit0.613.743.74SOPHSOPHiA GENETICS0.123.803.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AETSTEarth Science TechN/AGNFTGenfit2.24%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%ETSTEarth Science Tech24.90%GNFTGenfit4.20%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableETSTEarth Science Tech3294.30 million223.35 millionNot OptionableGNFTGenfit12050.00 million47.90 millionNot OptionableSOPHSOPHiA GENETICS52066.69 million62.19 millionNot OptionableETST, GNFT, ANNX, and SOPH HeadlinesRecent News About These CompaniesSOPHiA GENETICS (SOPH) Projected to Post Earnings on TuesdayMay 1 at 9:32 AM | marketbeat.comSOPHiA GENETICS expands AstraZeneca liquid biopsy testApril 30 at 7:05 PM | investing.comSOPHiA GENETICS Expands AstraZeneca Partnership to Advance Liquid Biopsy WorldwideApril 29, 2025 | msn.comSOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACRApril 28, 2025 | prnewswire.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025April 22, 2025 | prnewswire.comSophia Genetics, Precision for Medicine enter strategic partnershipApril 9, 2025 | markets.businessinsider.comPrecision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy CapabilitiesApril 8, 2025 | prnewswire.comSOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?March 21, 2025 | zacks.comMorgan Stanley Keeps Their Hold Rating on SOPHiA GENETICS (SOPH)March 20, 2025 | markets.businessinsider.comSOPHiA GENETICS (SOPH) Gets a Buy from BTIGMarch 18, 2025 | markets.businessinsider.comSOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTCMarch 18, 2025 | prnewswire.comSOPHiA GENETICS (SOPH) Receives a Buy from BTIGMarch 12, 2025 | markets.businessinsider.comBaby Sophia from embryo swap will stay with birth parents court rules on appealMarch 11, 2025 | msn.comDistrict Court rules to keep IVF child with birth mother following embryo mix-upMarch 10, 2025 | msn.comCourt overturns ruling that ordered toddler returned to genetic parents following embryo mix-upMarch 10, 2025 | msn.comSophia Genetics price target lowered to $5 from $6 at BTIGMarch 6, 2025 | markets.businessinsider.comSOPHiA GENETICS (SOPH) Gets a Buy from RBC CapitalMarch 5, 2025 | markets.businessinsider.comSOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comSOPHiA GENETICS Full Year 2024 Earnings: In Line With ExpectationsMarch 5, 2025 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comSophia Genetics sees FY25 revenue $72M-$76M, consensus $74.51MMarch 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETST, GNFT, ANNX, and SOPH Company DescriptionsAnnexon NASDAQ:ANNX$1.97 +0.12 (+6.20%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.97 0.00 (0.00%) As of 05/2/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Earth Science Tech OTCMKTS:ETST$0.14 -0.04 (-20.00%) As of 05/2/2025 03:35 PM EasternEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.Genfit NASDAQ:GNFT$4.22 +0.14 (+3.31%) As of 05/2/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.SOPHiA GENETICS NASDAQ:SOPH$3.03 +0.01 (+0.33%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.28 +0.25 (+8.22%) As of 05/2/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
